US EditionSun Pharma Announces FDA Approval of Next Generation BLU-U® Blue Light Photodynamic Therapy Illuminator for Actinic Keratosis
Summary by CNHI News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
All
Left
Center
Right
Sun Pharma gets USFDA approval for new device to treat skin disease
Pharma major Sun Pharmaceutical Industries on Friday said it has received approval from the US Food and Drug Administration (USFDA) for a new medical device that treats a skin disease called actinic keratoses. According to the official website of US National Center for Biotechnology Information (NCBI), the disease is “often associated with chronic sun exposure, (and) individuals with actinic keratosis may present with irregular, red, scaly papul…
Sun Pharma Announces FDA Approval of Next Generation BLU-U® Blue Light Photodynamic Therapy Illuminator for Actinic Keratosis
The BLU-U Model 4170E offers a compact, easy-to-use option with the same BLU-U safety and efficacy healthcare professionals have trusted for years.
·United States
Read Full ArticleCoverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
